ST. LOUIS, Sept. 21, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that J. David Burkhardt, M.D. of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, TX has surpassed 1,000 electrophysiology (EP) procedures performed with the Niobe® remote magnetic navigation system. Dr. Burkhardt is the first in the U.S. to achieve this significant milestone and one of the top five Niobe system users globally. More than 82,000 procedures have been conducted worldwide with the Niobe system.
“I rely on the Niobe system implicitly for my complex EP procedures,” said Dr. Burkhardt, who primarily treats complex arrhythmias and is considered an expert in the ablation of VT (ventricular tachycardia) and other complex arrhythmias. “At St. David’s, we maintain a high standard of excellence and are committed to employing the most state-of-the-art tools to improve the quality of life for our patients. Stereotaxis’ advanced, computer-controlled technology has allowed us to perform very complicated procedures safely and efficiently, and we have published excellent results using the system. In addition, we are able to reach areas of the heart that otherwise would not have been possible. As a result, we have achieved safer, higher quality ablations with the Niobe system compared to other approaches.”
Under the leadership of Executive Medical Director Dr. Andrea Natale, a world renowned EP professional, St. David’s Medical Center installed the Niobe system in 2009, becoming the first facility in central Texas to implement Stereotaxis technology. St. David’s has since adopted it as the standard of care for patients diagnosed with VT. After upgrading to the Niobe® ES system in 2011, Dr. Burkhardt described the new platform and compatible soft magnetic catheter as “able to optimize patient safety and navigate difficult cases with precision.”
Dr. Natale, Dr. Burkhardt, and the rest of the TCAI team are at the forefront of advancing treatment for cardiac arrhythmias and are looked to as trusted advisors by EP physicians from around the world. In addition to the numerous clinical studies previously released by TCAI on the effectiveness of Stereotaxis’ remote magnetic navigation technology, the upcoming American Heart Association Scientific Sessions in November will publish the latest TCAI research results on long-term outcomes of the treatment of VT using Stereotaxis technology.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
CONTACT: STXS Company Contact: Martin Stammer Chief Financial Officer 314-678-6155 STXS Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 firstname.lastname@example.org